Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01124552 · ClinicalTrials.gov registry record · Phase 2

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

A Phase 2 study of Facial Wrinkles and Lateral Canthal Lines, sponsored by Revance Therapeutics.

Completed
Registry status
Phase 2
Development phase
180
Enrollment target
1
Study location

NCT01124552 is a Phase 2 study of Facial Wrinkles and Lateral Canthal Lines that has completed, run by Revance Therapeutics. The registered enrollment target is 180 participants, above the 57-participant average among 6 other Facial Wrinkles trials with a reported enrollment target (216% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01124552, a Phase 2 study of Facial Wrinkles and Lateral Canthal Lines, has completed, sponsored by Revance Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if an investigational drug, called RT001 Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called lateral canthal lines, also known as crow's feet wrinkles.

Interventions

  • DRUG Placebo
  • OTHER Vehicle
  • DRUG RT001 Botulinum toxin type A (Dose A)
  • DRUG RT001 Botulinum Toxin Type A (Dose B)

Study Locations (1)

Florida

  • Dermatology Research Institute, LLC - Coral Gables

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2010-04
Est. Completion 2010-07
Phase Phase 2

Sponsor

Revance Therapeutics

27 total trials

What the Registry Record Tells You About NCT01124552

The ClinicalTrials.gov registry entry for NCT01124552 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 57-participant average among 6 other Facial Wrinkles trials with a reported enrollment target (216% higher). The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Facial Wrinkles appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT01124552 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT01124552 about?

NCT01124552 is a clinical study titled "A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults". The purpose of this study is to find out if an investigational drug, called RT001 Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called lateral canthal lines, also known as crow's feet wrinkles.

What is the current status of trial NCT01124552?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2010-04. Estimated completion is 2010-07.

What conditions does trial NCT01124552 study?

This clinical trial studies the following conditions: Facial Wrinkles, Lateral Canthal Lines, Crows Feet.

What interventions are being tested in trial NCT01124552?

The interventions under investigation include: Placebo (DRUG), Vehicle (OTHER), RT001 Botulinum toxin type A (Dose A) (DRUG), RT001 Botulinum Toxin Type A (Dose B) (DRUG).

Who is sponsoring clinical trial NCT01124552?

This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01124552 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Facial Wrinkles

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.